Table 2.

Summary of PKI concentrations after 2 weeks of treatment. PKI concentrations in tumor, skin, plasma and serum per cohort, determined by LC-MS after 10–14 days of treatment. Numbers depict median and range of concentrations based on 5 patients per cohort, unless otherwise indicated. NE, not evaluable. Achieved plasma and serum concentrations at t = 1 week (data not shown) and t = 2 weeks of treatment were highly comparable. Results for individual patients are shown in Table S1.

PKI Cohort	Tumor µM (Range)	Skin µM (Range)	Plasma µM (Range)	Serum µM (Range)
Sorafenib	10.0 (3.7–22.0)	6.3 (1.4–28.4)	4.8 (3.7–12.1)	6.9 (4.8–17.4)
Erlotinib	4.2 (0.9–10.8)	2.8 (2.1–6.7)	1.2 (0.9–4.0)	1.1 (0.9–4.4)
Dasatinib	2.0 (0.2–64.0)	0.4 (0.2–18.5)N = 4	0.012 (0.005–0.041)	0.009 (0.017–0.037)N = 3
Sunitinib	9.0 (2.3–50.0)	4.3 (0.5–9.7)N = 3	0.1 (0.1–0.2)	0.1 (0.1–0.2)
Vemurafenib	1326 (331–2347)N = 6	879 (120–2557)N = 8	98 (65–210)N = 7	108 (47–242)N = 8
Everolimus	3.5 (3.4–3.6)N = 2	NE	NE	NE